FSE

InvestmentPitch Media Video Discusses Nextech AR Solutions’ New Patent for AI Technology 3D Model Creation and 2nd Pending Spinout, Positioning Company for Exceptional 2023

Retrieved on: 
Wednesday, January 11, 2023
Metaverse, News, Saudi Research and Marketing Group, CSE, FSE, 3D, Research, Marketing, Patent, Iveco Bus, OTCQX, N29, NTAR, E-commerce, 3D printing

VANCOUVER, British Columbia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Nextech AR Solutions Corp. (OTCQX:NEXCF) (CSE:NTAR) (FSE:N29), a Metaverse Company and leading provider of augmented reality experience technologies and 3D model services, announced a patent update covering its artificial intelligence technology 3D model creation.

Key Points: 
  • VANCOUVER, British Columbia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Nextech AR Solutions Corp. (OTCQX:NEXCF) (CSE:NTAR) (FSE:N29), a Metaverse Company and leading provider of augmented reality experience technologies and 3D model services, announced a patent update covering its artificial intelligence technology 3D model creation.
  • At that time, the company began implementing this breakthrough part-based 3D model creation technology and by using what it calls “through composition of deformable parts” has expanded its library to more than 100,000 3D model parts.
  • These parts are used to create a 3D model as most 3D models are composed of several individual parts.
  • Investor Relations is handled by Lindsay Betts, who can be reached at 866-274-8493 Ext 7201 or by email at [email protected] .

Aduro Returns to CEM AlphaNorth Capital Event

Retrieved on: 
Wednesday, January 11, 2023
ACT, Mitacs, API, Shell, Oil, CSE, FSE, Natural science, CEM, Engineering, Growth, NSERC, Research, Letter, Plastic

SARNIA, Ontario, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (CSE: ACT) (OTCQB: ACTHF) (FSE: 9D50), a Canadian developer of patented water-based technologies to chemically recycle plastics, and to transform heavy crude and renewable oils into new-era resources and higher-value fuels, announced today that it will participate in the CEM AlphaNorth Capital Event in Nassau, Bahamas from January 20-23, 2023.

Key Points: 
  • SARNIA, Ontario, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Aduro Clean Technologies Inc. (“Aduro” or the “Company”) (CSE: ACT) (OTCQB: ACTHF) (FSE: 9D50), a Canadian developer of patented water-based technologies to chemically recycle plastics, and to transform heavy crude and renewable oils into new-era resources and higher-value fuels, announced today that it will participate in the CEM AlphaNorth Capital Event in Nassau, Bahamas from January 20-23, 2023.
  • During the event, Aduro will conduct one-on-one meetings with interested investors and other stakeholders.
  • "This conference provides an opportunity to talk to investors who are searching for high-growth companies in the clean technology sector like Aduro, presenting them with our accomplishments and discussing our future plans" said Ofer Vicus, CEO of Aduro.
  • "Aduro is well-positioned to continue its growth in 2023 and beyond, and we look forward to discussing our plans with investors at the CEM AlphaNorth Capital Event."

Recce Pharmaceuticals to be Granted Anti-Viral Patent in Australia for RECCE® Anti-Infectives

Retrieved on: 
Wednesday, January 11, 2023
RCE, Viral, Inhalation, Patent, Virus, Administration, HIV, Severe acute respiratory syndrome coronavirus 2, FSE, Recce, Treatment, ASX, Hepatitis, IP, Australian patent law, Pharmaceutical industry, Vaccine

SYDNEY, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce patent family three, “Anti-Virus Agent and Method for Treatment of Viral Infection.”

Key Points: 
  • SYDNEY, Australia, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Australian Patent Office issued notification of intent to grant Recce patent family three, “Anti-Virus Agent and Method for Treatment of Viral Infection.”
    “Receiving notice that this Australian patent application will proceed to grant is another milestone in the Company’s global IP strategy, and we are thrilled by the further validation of the potential importance of our infectious disease compounds,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • The Australian Patent is expected to grant claims relating to RECCE® 327 (R327) and anti-viral formulation RECCE® 529 (R529), most notably:
    Use of R327 or R529 for the treatment of viruses having a lipid envelope or coat, examples being SARS-CoV-2 and coronaviruses, influenza viruses, (human immunodeficiency virus) HIV, hepatitis, Ross River and herpes viruses
    Administration of R327 or R529 by oral, injection, inhalation and transdermal dose applications
    This is the final patent of family three (expiry: November 2037), following those already granted in the biggest pharmaceutical markets in the world such as China, Japan, Europe, Hong Kong, and the United States.

Terra Balcanica Extends Footprint of Shallow Polymetallic Cumavici Vein At Viogor-Zanik Project in Bosnia-Herzegovina

Retrieved on: 
Wednesday, January 11, 2023
News, Horizontal drillhole disposal, CSE, FSE, Galena, Brežani, TERA, Oil, Glass fiber, Uranium, Road, Sulfur

Terra Balcanica CEO, Dr. Aleksandar Mišković, commented: “The 2022 maiden drill program at Cumavici Ridge has been encouraging in confirming the hypothesis of identifying a shallow, high-grade polymetallic, epithermal vein-hosted mineralized system, while also confirming its down-dip and along-strike continuity.

Key Points: 
  • Terra Balcanica CEO, Dr. Aleksandar Mišković, commented: “The 2022 maiden drill program at Cumavici Ridge has been encouraging in confirming the hypothesis of identifying a shallow, high-grade polymetallic, epithermal vein-hosted mineralized system, while also confirming its down-dip and along-strike continuity.
  • It is very exciting to see the Cumavici Ridge target entirely open along strike allowing for continued step out and infill drilling.
  • Future drilling efforts will test the continuity of the 7.2 km long Cumavici polymetallic vein system along strike towards the northwest and southeast.
  • Additionally, the Company completed drilling at the Brezani skarn/porphyry target which is located over 12 km to the southeast from Cumavici (see Figure 1).

Nextech's Breakthrough Generative AI Positions Company for Breakout Revenue Growth in 2023

Retrieved on: 
Tuesday, January 10, 2023
Metaverse, CSE, FSE, 3D, PART, AI, Artificial intelligence, Legislation, AR, Growth, Patent, E-commerce, Letter, NTAR, One stop shop, 3D printing, Nex Entertainment

Nextech AR's generative AI is a game-changer by solving the multi-billion dollar 3D model supply problem for the ecommerce market with this proprietary AI technology.

Key Points: 
  • Nextech AR's generative AI is a game-changer by solving the multi-billion dollar 3D model supply problem for the ecommerce market with this proprietary AI technology.
  • At the time, the Company began to implement this breakthrough part-based 3D model creation technology.
  • With our breakthrough AI that we are continuously developing, we are becoming the global go-to 3D model supplier for ecommerce.
  • Our proprietary breakthrough AI perfectly positions us to take full advantage of the multi-billion dollar decade long 3D model mega-trend!"

Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial

Retrieved on: 
Tuesday, January 10, 2023
CWY, CSE, FSE, AUD, FDA, MEAI, Therapy, Clinical trial, Good, GMP, Pharmaceutical industry

Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND) (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, announced that it has successfully manufactured batches of its drug candidate, MEAI-based molecule CMND-100, for use in its first in-human clinical trial.

Key Points: 
  • Tel Aviv, Israel / Vancouver, Canada, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (CSE: CMND) (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, announced that it has successfully manufactured batches of its drug candidate, MEAI-based molecule CMND-100, for use in its first in-human clinical trial.
  • “Having our drug candidate ready to be tested is a major milestone toward our first in-human clinical trial,” said Dr. Adi Zuloff-Shani, Clearmind’s Chief Executive Officer.
  • “Our pre-clinical positive results indicated the potential of our unique treatment for AUD.
  • We continue to execute the final steps necessary in order to commence our clinical program.”
    The drug candidate was produced under GMP (Good Manufacturing Process) conditions to comply with FDA requirements.

Bingo Main Gold Discovery 550 Meters x 175 Meters Remains Open - Drill Ready - Golden Triangle BC

Retrieved on: 
Tuesday, January 10, 2023
Metallica, Golden, Zinc, Copper, THIS, Eskay Creek, National instrument, ALS, Channel, FSE, QA/QC, Silver, SSW, Talus, Bingo, Maine, Foot, SELL, ISO 9001:2008, Coast Range Arc, Soil, National Instrument 43-101, Plasma, VMS, Vein, Anomaly, ID, GPS, Quartz, TSX, Lead, Golden Triangle, ISO, Nature, Gold, Granite, Silviculture, Dredging, Uranium, Limestone, Midas, Equilateral triangle, Arbitrage betting

VANCOUVER, British Columbia, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Juggernaut Exploration Ltd (JUGR.V) (OTCQB: JUGRF) (FSE: 4JE) (the “Company” or “Juggernaut”) is pleased to report results from the 2022 field program on its 100% controlled Bingo property located within the Eskay Rift region of the Golden Triangle, British Columbia. Grab samples assaying up to 7.39 gpt Au were collected along the Bingo Main Zone which was extended from 320 m by 175 m to 550 m by 175 m (see map). This season’s surface grab and soil sampling, ground magnetic survey, and drone survey together with the historic data compiled by the geologic team strongly indicate the presence of an extensive gold-mineralizing system on the Bingo property that is drill ready and remains open. The Company is planning an inaugural drill program in 2023 comprising up to 2000 m of drilling from up to 4 pads.

Key Points: 
  • The Bingo Main Zone is a drill ready zone containing gold mineralized grab, chip and channel samples over an area of 550 metres x 175 metres.
  • One-hundred forty-two (142) channel, chip, and grab samples were collected from the Main Zone and of these, 110 samples (77 %) contained gold mineralization.
  • Both properties are within the Eskay Rift known to be a fertile area for mineral deposits in the Golden Triangle.
  • The Metallica zone is drill ready and fully permitted, and the Company is planning a maiden drill program for 2023.

Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes

Retrieved on: 
Tuesday, January 10, 2023
Cell, FSE, TSX, IPSC, EVO, Hypoglycemia, Patient, Diabetes, Type 1 diabetes, Clinical trial, PSH, Pharmaceutical industry, Vaccine, Evotec, T1D

This progress includes advancement of Evotec’s iPSC derived islet-like clusters in combination with Sernova’s implantable Cell Pouch™ device toward a first-in-human Phase 1/2 clinical trial for the treatment of patients with T1D and severe hypoglycemia slated for regulatory filing in 2024.

Key Points: 
  • This progress includes advancement of Evotec’s iPSC derived islet-like clusters in combination with Sernova’s implantable Cell Pouch™ device toward a first-in-human Phase 1/2 clinical trial for the treatment of patients with T1D and severe hypoglycemia slated for regulatory filing in 2024.
  • The objective of the collaboration is to produce an off-the-shelf, commercially viable, ethically derived cell therapy treatment for people suffering from T1D.
  • The treatment would include Sernova’s Cell Pouch System™ incorporating Evotec’s iPSC-derived islet-like clusters.
  • The combination product is anticipated to be the first treatment of its kind to reach clinical testing for T1D.

Patriot Appoints Vice President ESG and Senior Advisor Environment and Permitting to its Team

Retrieved on: 
Monday, January 9, 2023
Mining, Community, Windfall, Suite (music), FSE, Social, Eeyou Istchee James Bay Regional Government, Cree, Water, ASX, ESG, First Nations, DFO, Occupational Safety and Health Act 1994, Senior management, Social Security Government Pension Offset, Osisko Mining, MBA, Gold, Oil, Patriot, Environment, Eeyou Istchee (territory)

VANCOUVER, British Columbia and SYDNEY, Australia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Patriot Battery Metals Inc. (the “Company” or “Patriot”) (TSX-V:PMET) (ASX: PMT) (OTCQX: PMETF) (FSE: R9GA) is pleased to announce the appointment of Alix Drapack, P.Eng., MBA, ICD.D to its Management Team in the role of Vice President Environment, Social and Governance (ESG). Ms. Drapack will oversee the company’s ESG activities including Environment, Community relations and First Nation relations, agreements, and partnerships. The company is also pleased to announce that Ms. Andrée Drolet, P.Eng. has joined the PMET team as senior advisor Environment and Permitting. Ms. Drapack and Ms. Drolet are two highly experienced professionals in their respective fields and will be instrumental for the advancement of the Corvette Property located in the Eeyou Istchee James Bay Region of Quebec.

Key Points: 
  • Ms. Drapack will oversee the company’s ESG activities including Environment, Community relations and First Nation relations, agreements, and partnerships.
  • has joined the PMET team as senior advisor Environment and Permitting.
  • The Patriot team has completed an impressive amount of ESG work to date as an exploration company.
  • The permitting path has strong foundation, and we look forward to progressing the environmental assessment process through to a successful completion”.

Reliq Health Contracts with Current Large Healthcare Network Client in Florida Adding Additional 34 New Hospital Clients to its iUGO Care platform – Video on InvestmentPitch Media

Retrieved on: 
Monday, January 9, 2023
News, Hospital, FSE, CMS, Centers for Medicare & Medicaid Services, Quality of life, RHT, Hip, Medicare, Health care, Patient, Heart failure, CARE

A Media Snippet accompanying this announcement is available by clicking on the image or link below:

Key Points: 
  • A Media Snippet accompanying this announcement is available by clicking on the image or link below:
    For more information, please view the InvestmentPitch Media video which provides additional news about the company.
  • The video is available for viewing on “ InvestmentPitch ” or on “ YouTube ”.
  • Based in Hamilton, Ontario, with offices in Florida and Texas, Reliq specializes in developing innovative Virtual Care solutions for the multi-billion dollar healthcare market.
  • The company’s powerful iUGO CARE platform supports care coordination and community-based virtual healthcare.